225Ac-ABD147 — Investigational Agent
Radiopharmaceutical · Phase 1 · Abdera Therapeutics
Mechanism of Action
Actinium-225 alpha-emitting radioligand targeting DLL3, engineered on a modular antibody-based platform to deliver cytotoxic alpha radiation to DLL3-positive small cell lung cancer and large cell neuroendocrine carcinoma. Optimized pharmacokinetics aim to maximize tumor uptake while limiting normal-tissue dose.
Investigational Indications
- DLL3-expressing small cell lung cancer
- Large cell neuroendocrine carcinoma of the lung